journal article·2010-01

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting

Marie Morille, Tristan Montier, Pierre Legras, Nathalie Carmoy, Priscille Brodin, Bruno Pitard, Jean-Pierre Benoît, Catherine Passirani

Biomaterials· Volume 31· Issue 2
Publisher page

Abstract

Systemic gene delivery systems are needed for therapeutic application to organs that are inaccessible by percutaneous injection. Currently, the main objective is the development of a stable and non-toxic vector that can encapsulate and deliver foreign genetic material to target cells. To this end, DNA, complexed with cationic lipids i.e. DOTAP/DOPE, was encapsulated into lipid nanocapsules (LNCs) leading to the formation of stable nanocarriers (DNA LNCs) with a size inferior to 130 nm. Amphiphilic and flexible poly (ethylene glycol) (PEG) polymer coatings [PEG lipid derivative (DSPE-mPEG(2000)) or F108 poloxamer] at different concentrations were selected to make DNA LNCs stealthy. Some of these coated lipid nanocapsules were able to inhibit complement activation and were not phagocytized in vitro by macrophagic THP-1 cells whereas uncoated DNA LNCs accumulated in the vacuolar compartment of THP-1 cells. These results correlated with a significant increase of in vivo circulation time in mice especially for DSPE-mPEG(2000) 10 mm and an early half-life time (t(1/2) of distribution) 5-fold greater than for non-coated DNA LNCs (7.1 h vs 1.4 h). Finally, a tumor accumulation assessed by in vivo fluorescence imaging system was evidenced for these coated LNCs as a passive targeting without causing any hepatic damage.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (36)

Show source-provided references
1. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer10.1016/j.biomaterials.2008.04.036 ↗
2. Activation of the complement system at the interface between blood and artificial surfaces10.1016/0142-9612(88)90066-X ↗
3. Parameters influencing the stealthiness of colloidal drug delivery systems10.1016/j.biomaterials.2006.03.039 ↗
4. A novel phase inversion-based process for the preparation of lipid nanocarriers10.1023/A:1016121319668 ↗
5. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake10.1002/jbm.a.30711 ↗
6. The encapsulation of DNA molecules within biomimetic lipid nanocapsules10.1016/j.biomaterials.2009.03.009 ↗
7. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
8. Evaluation of polyether–polyethyleneimine graft copolymers as gene transfer agents10.1038/sj.gt.3301052 ↗
9. Altered organ accumulation of oligonucleotides using polyethyleneimine grafted with poly(ethylene oxide) or pluronic as carriers10.1080/10611860290016711 ↗
10. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles10.1089/104303402760293592 ↗
11. Pluronic block copolymers: novel functional molecules for gene therapy10.1016/S0169-409X(02)00018-2 ↗
12. The influence of lipid nanocapsule composition on their size distribution10.1016/S0928-0987(02)00241-5 ↗
13. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats10.1158/1535-7163.MCT-06-0289 ↗
14. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system10.1016/S0024-3205(97)01175-2 ↗
15. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester
16. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗
17. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery10.1023/A:1010931127745 ↗
18. Novel long-circulating lipid nanocapsules10.1023/B:PHAM.0000045229.87844.21 ↗
19. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments10.1016/j.biomaterials.2007.05.014 ↗
20. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators10.1016/0142-9612(95)00322-3 ↗
21. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel10.1016/j.ijpharm.2007.06.014 ↗
22. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery10.1089/hum.1996.7.12-1437 ↗
23. Liposome–complement interactions in rat serum: implications for liposome survival studies10.1016/0005-2736(94)90231-3 ↗
24. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface10.1002/elps.200410145 ↗
25. Interactions of liposomes with the reticuloendothelial system. II: nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages10.1016/0167-4889(82)90120-3 ↗
26. Biodegradable long-circulating polymeric nanospheres10.1126/science.8128245 ↗
27. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time10.1016/0014-5793(96)00452-8 ↗
28. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression10.1016/j.bbamem.2005.02.001 ↗
29. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting10.1016/j.ijpharm.2009.05.065 ↗
30. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells10.1016/S0005-2760(97)00169-0 ↗
31. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules10.1016/S0142-9612(01)00043-6 ↗
32. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation10.1021/bc0255586 ↗
33. RNAi-mediated gene silencing in non-human primates10.1038/nature04688 ↗
34. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties10.1038/sj.gt.3300965 ↗
35. Stabilized plasmid-lipid particles: construction and characterization10.1038/sj.gt.3300821 ↗
36. Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties10.1016/S0005-2736(99)00059-0 ↗